CS
RUBY

Credit Suisse’s Rubius Therapeutics, Inc RUBY Stock Holding History

Credit Suisse’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-24
Closed – – 4474
2022
Q2 		$0 Sell
24
-28,593
-100% -$48K ﹤0.01% 4542
2022
Q1 		$158K Buy
28,617
+1,743
+6% +$11.1K ﹤0.01% 3423
2021
Q4 		$259K Buy
26,874
+1,091
+4% +$15.1K ﹤0.01% 4179
2021
Q3 		$461K Buy
25,783
+1,553
+6% +$33.8K ﹤0.01% 3857
2021
Q2 		$592K Buy
24,230
+3,999
+20% +$100K ﹤0.01% 3739
2021
Q1 		$536K Sell
20,231
-11,440
-36% -$167K ﹤0.01% 3725
2020
Q4 		$240K Buy
31,671
+14,746
+87% +$87.6K ﹤0.01% 4048
2020
Q3 		$84K Sell
16,925
-3,197
-16% -$16.9K ﹤0.01% 3933
2020
Q2 		$121K Buy
20,122
+4,130
+26% +$24.4K ﹤0.01% 3820
2020
Q1 		$71K Sell
15,992
-469
-3% -$3.48K ﹤0.01% 3879
2019
Q4 		$156K Sell
16,461
-5,357
-25% -$51.8K ﹤0.01% 4029
2019
Q3 		$171K Buy
21,818
+4,690
+27% +$54.7K ﹤0.01% 3899
2019
Q2 		$269K Buy
+17,128
New +$276K ﹤0.01% 3736

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse's RUBY Position: Q3 2022 in Review

Credit Suisse sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 24 shares.

Credit Suisse first reported a position in RUBY in Q2 2019 and held it in 13 quarters. The position peaked at $592K in Q2 2021. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • Credit Suisse reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 24 Rubius Therapeutics, Inc shares in Q3 2022.
  • Credit Suisse first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 13 quarters.
  • Credit Suisse's Rubius Therapeutics, Inc position peaked at $592K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.